JP2000514837A - 経皮浸透エンハンサーを使用する皮下筋肉組織へのカテコールアミン及び関連化合物の局所投与 - Google Patents
経皮浸透エンハンサーを使用する皮下筋肉組織へのカテコールアミン及び関連化合物の局所投与Info
- Publication number
- JP2000514837A JP2000514837A JP10548365A JP54836598A JP2000514837A JP 2000514837 A JP2000514837 A JP 2000514837A JP 10548365 A JP10548365 A JP 10548365A JP 54836598 A JP54836598 A JP 54836598A JP 2000514837 A JP2000514837 A JP 2000514837A
- Authority
- JP
- Japan
- Prior art keywords
- enhancer
- composition
- muscle tissue
- mixtures
- tyrosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/05—Stick
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.皮下筋肉組織の臨床上認めることのできる緊張が増大するように、活性成分 として約0.1−約10重量%のカテコールアミン活性を示す化合物、並びに有 効な量の経皮浸透増強剤を含む組成物を筋肉組織を覆う病気にかかった皮膚領域 に局所的に適用することからなる皮下筋肉組織の治療法。 2.組成物が約0.25−約5重量%の活性成分を含む請求項1の方法。 3.経皮浸透増強剤が化学的増強剤である請求項1の方法。 4.増強剤が、スルホキシド、アルコール、ポリオール、アルカン、脂肪酸、エ ステル、アミン、アミド、テルペン、表面活性剤、シクロデキストリン、及びこ れらの混合物からなる群から選ばれる請求項3の方法。 5.増強剤が約10.5cal1/2cm3/2の溶解度パラメータを有する請求項4 の方法。 6.増強剤が、オレイン酸、尿素、アスコルビン酸の飽和脂肪酸エステル、トコ トリエノール及びこれらの混合物からなる群から選ばれる請求項3の方法。 7.アスコルビン酸の脂肪酸エステルがアスコルビルパルミテートである請求項 6の方法。 8.経皮浸透増強剤が物理的増強剤である請求項1の方法。 9.物理的増強剤が、皮膚水和増強剤、吸蔵装置、ヒドロコロイドパッチ、親油 性浸透剤、脱脂質化剤、エレクトロポレーション、イオン泳動、及び超音波から なる群から選ばれる請求項8の方法。 10.増強剤が、化学的増強剤及び物理的増強剤からなる請求項1の方法。 11.活性成分がチロシンである請求項1の方法。 12.組成物が約1−約3重量%のチロシンを含む請求項11の方法。 13.組成物がさらに神経伝達物質の合成を増強する他の成分を含む請求項1の 方法。 14.組成物がさらにピリドキシン、パントテン酸カルシウム、パントテン酸及 びこれらの混合物からなる群から選ばれる化合物を含む請求項1の方法。 15.組成物がさらに抗酸化剤を含む請求項1の方法。 16.皮下筋肉組織中の筋緊張を臨床的に認められるように増大するために、ド ーパ、チロシン、フェニルアラニン及びこれらの混合物からなる群から選ばれる 活性成分を約0.25−約5重量%含む組成物を皮膚科学的に許容できる担体中 で組織を覆う病気にかかった皮膚領域に局所的に適用することからなる老化する 皮下筋肉組織の局所治療法において、組成物が、さらに、約0.1−約10重量 %のスルホキシド、アルコール、ポリオール、アルカン、脂肪酸、エステル、ア ミン及びアミド、テルペン、表面活性剤、シクロデキストリン及びこれらの混合 物からなる群から選ばれる浸透増強剤を含む方法。 17.浸透増強剤が、アスコルビン酸の飽和脂肪酸エステル、オレイン酸、尿素 、トコトリエノール、及びこれらの混合物からなる群から選ばれる請求項16の 方法。 18.チロシン、並びにチロシンを筋肉組織に伝達するのに有効な量のスルホキ シド、アルコール、ポリオール、アルカン、脂肪酸、エステル、アミン及びアミ ド、テルペン、表面活性剤、シクロデキストリン及びこれらの混合物からなる群 から選ばれる化学的浸透増強剤を含む組成物を、老化する皮下筋肉組織の覆った 表皮に投与することからなる、該筋肉組織を治療する方法。 19.組成物が約0.25−約5重量%のチロシンを含有する請求項18の方法 。 20.組成物がアスコルビルパルミテートからなる請求項18の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/851,222 US5879690A (en) | 1995-09-07 | 1997-05-05 | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers |
US08/851,222 | 1997-05-05 | ||
PCT/US1998/009106 WO1998050014A1 (en) | 1997-05-05 | 1998-05-04 | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000514837A true JP2000514837A (ja) | 2000-11-07 |
Family
ID=25310273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10548365A Pending JP2000514837A (ja) | 1997-05-05 | 1998-05-04 | 経皮浸透エンハンサーを使用する皮下筋肉組織へのカテコールアミン及び関連化合物の局所投与 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5879690A (ja) |
EP (1) | EP0989845A4 (ja) |
JP (1) | JP2000514837A (ja) |
BR (1) | BR9809212A (ja) |
CA (1) | CA2287477C (ja) |
GB (1) | GB2339536A (ja) |
IL (1) | IL132338A (ja) |
WO (1) | WO1998050014A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005534639A (ja) * | 2002-05-29 | 2005-11-17 | ユニリーバー・ナームローゼ・ベンノートシヤープ | アミン塩を含有する化粧料組成物の臭気の抑制 |
JP2013515771A (ja) * | 2009-12-28 | 2013-05-09 | エヌ・ブイ・ペリコーン・リミテッド・ライアビリティ・カンパニー | 局所用アシルグルタチオン製剤 |
KR102130240B1 (ko) * | 2019-01-07 | 2020-07-03 | 연세대학교 산학협력단 | 탄소수 14 내지 17의 직쇄 알칸을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물 |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7396526B1 (en) | 1998-11-12 | 2008-07-08 | Johnson & Johnson Consumer Companies, Inc. | Skin care composition |
US6521237B2 (en) | 1998-11-12 | 2003-02-18 | Johnson & Johnson Consumer Companies, Inc. | Skin care composition |
DE60045153D1 (de) * | 1999-04-13 | 2010-12-09 | Hisamitsu Pharmaceutical Co | Zubereitungen zur perkutanen absorption |
JP5106715B2 (ja) * | 1999-09-24 | 2012-12-26 | アルロン・ジャパン株式会社 | L−アスコルビン酸、l−アスコルビン酸誘導体の皮膚真皮層への放出方法に使用するための組成物 |
US6645520B2 (en) | 1999-12-16 | 2003-11-11 | Dermatrends, Inc. | Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers |
US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6673363B2 (en) | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
US20030104041A1 (en) * | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
US6719997B2 (en) | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
US6602912B2 (en) | 2000-06-30 | 2003-08-05 | Dermatrends, Inc. | Transdermal administration of phenylpropanolamine |
US6562368B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers |
US6562370B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers |
US6558695B2 (en) | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
US6562369B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers |
CA2407657C (en) * | 2000-05-09 | 2010-07-27 | Unilever Plc | Cosmetic skin care compositions containing pulegone |
FR2813188B1 (fr) * | 2000-08-25 | 2003-01-17 | Sederma Sa | Utilisation de la tyramine dans des compositions cosmetiques destinees a eclaicir la peau |
JP3730102B2 (ja) * | 2000-09-14 | 2005-12-21 | ポーラ化成工業株式会社 | 透過促進用の皮膚外用剤 |
JP2004509920A (ja) * | 2000-09-29 | 2004-04-02 | ボード オブ トラスティーズ オペレーティング ミシガン ステート ユニヴァーシティ | カテコールアミン医薬組成物および方法 |
US20040213754A1 (en) * | 2000-10-02 | 2004-10-28 | Cole Curtis A. | Method for cleansing sensitive skin using an alkanolamine |
KR20020027198A (ko) * | 2000-10-02 | 2002-04-13 | 차알스 제이. 메츠 | 염증과 홍반의 완화방법 |
US6607735B2 (en) * | 2000-12-21 | 2003-08-19 | Johnson & Johnson Consumer Companies, Inc. | Method for reducing the appearance of dark circles under the eyes |
US6743433B2 (en) * | 2001-07-06 | 2004-06-01 | Nicholas V. Perricone | Treatment of acne using alkanolamine compositions |
US6500857B1 (en) | 2001-08-16 | 2002-12-31 | Nicholas V. Perricone | Subcutaneous muscle treatment using electronic stimulation and topical compositions |
WO2003028691A2 (en) * | 2001-09-27 | 2003-04-10 | Johnson & Johnson Consumer France S.A.S. | Stable compositions containing ethanolamine derivatives and glucosides |
US20050238730A1 (en) * | 2001-11-21 | 2005-10-27 | Agnes Le Fur | Compositions comprising an ethanolamine derivative and organic metal salts |
MY139332A (en) * | 2002-05-22 | 2009-09-30 | Hovid Berhad | Hair growth formulation |
US20040018237A1 (en) | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
SE0301862D0 (sv) * | 2003-06-26 | 2003-06-26 | Jan Faergeman | Sätt att inhibera tillväxten av mot antibiotika resistenta bakterier |
CA2545584C (en) | 2003-11-17 | 2012-10-23 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of metabolic disorders |
US20050192229A1 (en) * | 2004-02-27 | 2005-09-01 | Perricone Nicholas V. | Topical glutathione treatments |
BRPI0517088A (pt) * | 2004-11-17 | 2008-09-30 | Biomarin Pharm Inc | formulação de comprimido estável |
US20060193814A1 (en) * | 2005-02-25 | 2006-08-31 | Eduardo Ruvolo | Compositions for the treatment of signs of aging |
US8221046B2 (en) * | 2005-02-25 | 2012-07-17 | Johnson & Johnson Consumer Companies, Inc. | Compositions containing amines and use thereof |
US20060193818A1 (en) * | 2005-02-25 | 2006-08-31 | Southall Michael D | Compositions containing amines and use thereof |
US8278359B2 (en) * | 2005-02-25 | 2012-10-02 | Johnson & Johnson Consumer Companies, Inc. | Compositions containing amines and use thereof to treat acne or reduce the appearance of oil or pores on the skin |
US20060193777A1 (en) * | 2005-02-25 | 2006-08-31 | Southall Michael D | Method of screening compounds for potential efficacy for the treatment of signs of aging |
US7547434B2 (en) * | 2005-09-09 | 2009-06-16 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for mitigating skin irritation |
GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
US20070248696A1 (en) * | 2006-04-25 | 2007-10-25 | Mind Sports Nutrition Inc. | Composition and method for enhancing neuromuscular facilitation and cognitive functions |
FR2908989B1 (fr) * | 2006-11-23 | 2012-08-17 | Oreal | Composition cosmetique comprenant au moins un ester volatil |
US7652504B2 (en) * | 2006-12-13 | 2010-01-26 | Apple Inc. | Low latency, power-down safe level shifter |
US7834662B2 (en) * | 2006-12-13 | 2010-11-16 | Apple Inc. | Level shifter with embedded logic and low minimum voltage |
US20080152592A1 (en) * | 2006-12-21 | 2008-06-26 | Bayer Healthcare Llc | Method of therapeutic drug monitoring |
US20100210932A1 (en) * | 2007-03-20 | 2010-08-19 | Bayer Healthcare Llc | Method of analyzing an analyte |
JP5754885B2 (ja) * | 2007-06-21 | 2015-07-29 | 株式会社フジモト・コーポレーション | 経皮または経粘膜投与用組成物 |
US8102728B2 (en) * | 2009-04-07 | 2012-01-24 | Apple Inc. | Cache optimizations using multiple threshold voltage transistors |
US7995410B2 (en) * | 2009-06-26 | 2011-08-09 | Apple Inc. | Leakage and NBTI reduction technique for memory |
US20110151525A1 (en) * | 2009-12-23 | 2011-06-23 | Muhammad Kaiyal | Enzymatic production of unsaturated fatty acids esters of ascorbic acid in solvent-free system |
US8580742B2 (en) | 2010-03-05 | 2013-11-12 | N.V. Perricone Llc | Topical glutathione formulations for menopausal skin |
US20110160144A1 (en) * | 2009-12-28 | 2011-06-30 | Perricone Nicholas V | Topical Acyl Glutathione Formulations |
US8609604B2 (en) | 2009-12-28 | 2013-12-17 | N.V. Perricone Llc | Methods of improving the appearance of aging skin |
US20110245183A1 (en) | 2010-04-06 | 2011-10-06 | Perricone Nicholas V | Topical Uses of Szeto-Schiller Peptides |
US20110245182A1 (en) | 2010-04-06 | 2011-10-06 | Perricone Nicholas V | Topical Uses of Szeto-Schiller Peptides |
WO2011152832A1 (en) | 2010-06-04 | 2011-12-08 | N.V. Perricone Llc | Methods of use of nitroalkene compositions in dermatologic applications to prevent or treat skin aging |
US20120083452A1 (en) * | 2010-09-30 | 2012-04-05 | Perricone Nicholas V | Topical Anesthetic Uses of Szeto-Schiller Peptides |
US8414869B2 (en) | 2010-11-30 | 2013-04-09 | N.V. Perricone Llc | Melanin promoting topical composition |
US9034926B2 (en) | 2010-12-30 | 2015-05-19 | Nicholas V. Perricone | Topical nitrone spin trap compositions for psoriasis |
CN103547258B (zh) | 2011-03-17 | 2017-10-20 | 特兰斯德梅尔生物工艺股份有限公司 | 局部一氧化氮系统及其使用方法 |
US8609618B2 (en) | 2011-03-25 | 2013-12-17 | N.V. Perricone Llc | Topical palmitoyl glutathione formulations |
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US8871262B2 (en) * | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US20160136169A1 (en) * | 2012-09-19 | 2016-05-19 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of tetrahydrobiopterin and related compounds |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US8871254B2 (en) * | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
BR112018072539A2 (pt) | 2016-05-05 | 2019-03-26 | Aquestive Therapeutics, Inc. | composições de epinefrina de administração aumentada |
CN111148512A (zh) * | 2017-09-26 | 2020-05-12 | 阿奎斯蒂弗医疗股份有限公司 | 包含渗透增强剂的递送药物组合物 |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
WO2020212948A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
WO2021167123A1 (ko) * | 2020-02-18 | 2021-08-26 | 연세대학교 산학협력단 | 탄소수 14 내지 17의 직쇄 알칸을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물 |
CN112924598B (zh) * | 2021-01-28 | 2023-07-28 | 广州市妇女儿童医疗中心 | 生物胺类神经递质的定量分析方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4557934A (en) * | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4647453A (en) * | 1984-10-18 | 1987-03-03 | Peritain, Ltd. | Treatment for tissue degenerative inflammatory disease |
US4590067A (en) * | 1984-10-18 | 1986-05-20 | Peritain, Ltd. | Treatment for periodontal disease |
US4772591A (en) * | 1985-09-25 | 1988-09-20 | Peritain, Ltd. | Method for accelerated wound healing |
US4938969A (en) * | 1988-11-14 | 1990-07-03 | Milor Scientific, Ltd. | Method for the treatment of aging or photo-damaged skin |
US5554647A (en) * | 1989-10-12 | 1996-09-10 | Perricone; Nicholas V. | Method and compositions for treatment and/or prevention of skin damage and aging |
US5376361A (en) * | 1993-01-13 | 1994-12-27 | Perricone; Nicholas V. | Method and compositions for topical application to the skin for prevention and/or treatment of radiation-induced skin damage |
US5643586A (en) * | 1995-04-27 | 1997-07-01 | Perricone; Nicholas V. | Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds |
DE29612123U1 (de) * | 1996-07-11 | 1996-09-12 | Kafl Johann | Dermapermeables (hautdurchlässiges) Gel (Salbe) zur subcutanen Lipidmetabolisierung (Unterhautfettverbrennung) und Behandlung von Cellulite |
-
1997
- 1997-05-05 US US08/851,222 patent/US5879690A/en not_active Expired - Lifetime
-
1998
- 1998-05-04 CA CA002287477A patent/CA2287477C/en not_active Expired - Lifetime
- 1998-05-04 IL IL13233898A patent/IL132338A/en not_active IP Right Cessation
- 1998-05-04 JP JP10548365A patent/JP2000514837A/ja active Pending
- 1998-05-04 BR BR9809212-0A patent/BR9809212A/pt not_active Application Discontinuation
- 1998-05-04 WO PCT/US1998/009106 patent/WO1998050014A1/en not_active Application Discontinuation
- 1998-05-04 EP EP98920978A patent/EP0989845A4/en not_active Withdrawn
- 1998-05-04 GB GB9925341A patent/GB2339536A/en not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005534639A (ja) * | 2002-05-29 | 2005-11-17 | ユニリーバー・ナームローゼ・ベンノートシヤープ | アミン塩を含有する化粧料組成物の臭気の抑制 |
JP2013515771A (ja) * | 2009-12-28 | 2013-05-09 | エヌ・ブイ・ペリコーン・リミテッド・ライアビリティ・カンパニー | 局所用アシルグルタチオン製剤 |
KR102130240B1 (ko) * | 2019-01-07 | 2020-07-03 | 연세대학교 산학협력단 | 탄소수 14 내지 17의 직쇄 알칸을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물 |
Also Published As
Publication number | Publication date |
---|---|
IL132338A0 (en) | 2001-03-19 |
GB9925341D0 (en) | 1999-12-29 |
BR9809212A (pt) | 2000-06-27 |
CA2287477C (en) | 2008-09-16 |
IL132338A (en) | 2004-08-31 |
GB2339536A (en) | 2000-02-02 |
EP0989845A4 (en) | 2004-04-07 |
US5879690A (en) | 1999-03-09 |
EP0989845A1 (en) | 2000-04-05 |
WO1998050014A1 (en) | 1998-11-12 |
CA2287477A1 (en) | 1998-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5879690A (en) | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers | |
US5643586A (en) | Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds | |
US5554647A (en) | Method and compositions for treatment and/or prevention of skin damage and aging | |
EP3236903B1 (en) | Methods and formulations for transdermal administration | |
US5409693A (en) | Method for treating and preventing sunburn and sunburn damage to the skin | |
US5574063A (en) | Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage | |
KR20000026159A (ko) | 국소 적용을 위해 아스코르브산, 아스코르브산 유도체, 및/또는아스코르브산을 함유하는 추출물을 안정화시키는 방법 | |
JP2003530330A (ja) | ポリエニルホスファチジルコリンを使用する皮膚の損傷の治療 | |
AU780426B2 (en) | Method for reducing the appearance of dark circles under the eyes | |
MXPA05001358A (es) | Composiciones cosmeticas con propiedades humectantes de la piel, de duracion prolongada. | |
US20070041931A1 (en) | Compositions Comprising Soy Products and Dioic Acids | |
US11730690B2 (en) | Use of ambroxol to improve skin barrier function | |
US7547434B2 (en) | Compositions and methods for mitigating skin irritation | |
GB2304573A (en) | Skin care composition comprising sunscreen, humectant and exfolliant | |
JP2002161027A (ja) | 炎症および紅斑の減少方法および組成物 | |
US6979459B1 (en) | Treatment of skin damage using polyenylphosphatidycholine | |
US6500857B1 (en) | Subcutaneous muscle treatment using electronic stimulation and topical compositions | |
RU2304428C2 (ru) | Композиция на основе сложного эфира диосгенина для топического нанесения | |
RU2736504C1 (ru) | Система энхансеров трансдермального переноса и косметические композиции на ее основе | |
US20050019354A1 (en) | Topical benfotiamine treatments | |
JPH11116458A (ja) | 皮膚外用剤組成物 | |
EP1545451A1 (en) | Compositions comprising soy products and organic salts of certain metals | |
MXPA99010171A (en) | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers | |
US20080026074A1 (en) | Method of short term skin wrinkles correction using strontium divalent ion | |
JP2013538866A (ja) | 皮膚治療のための組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031127 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040302 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060829 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061226 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070329 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070720 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20071108 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081119 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081125 |